Navigating Survivorship and Self-Advocacy After Childhood Cancer: Maria’s Journey with Mosaic Variegated Aneuploidy Syndrome 3 (MVA 3)

My story began before I was old enough to understand it. Childhood cancer shaped my body and my life long before I had words for fear, pain, or survival. That…

Continue Reading Navigating Survivorship and Self-Advocacy After Childhood Cancer: Maria’s Journey with Mosaic Variegated Aneuploidy Syndrome 3 (MVA 3)

Cabaletta Bio Advances Rare Disease Treatment with Pioneering Myositis Trial and Innovative Manufacturing Breakthrough

Cabaletta Bio has announced significant progress in its development of chimeric autoantibody receptor T cell (CAAR-T) therapies, marking a major milestone with the initiation of its first pivotal myositis trial…

Continue Reading Cabaletta Bio Advances Rare Disease Treatment with Pioneering Myositis Trial and Innovative Manufacturing Breakthrough

FDA Advances Rivoceranib-Camrelizumab Combination: A Promising Breakthrough for First-Line Unresectable Hepatocellular Carcinoma Treatment

Elevar Therapeutics has achieved a significant regulatory milestone with the US Food and Drug Administration's acceptance of a resubmitted New Drug Application for rivoceranib in combination with camrelizumab as first-line…

Continue Reading FDA Advances Rivoceranib-Camrelizumab Combination: A Promising Breakthrough for First-Line Unresectable Hepatocellular Carcinoma Treatment

IQIRVO: A Revolutionary PPAR Agonist Transforms Second-Line Treatment for Primary Biliary Cholangitis

Primary biliary cholangitis (PBC) represents a chronic, progressive autoimmune liver disease characterized by the destruction of small bile ducts, leading to cholestasis and potentially fatal complications. Affecting millions globally with…

Continue Reading IQIRVO: A Revolutionary PPAR Agonist Transforms Second-Line Treatment for Primary Biliary Cholangitis

Beyond the Diagnosis: Otsuka’s “All of ADHD” Campaign Reframes Healthcare Provider Perspectives on a Complex Condition

  • Post author:
  • Post category:ADHD

Otsuka has launched an ambitious awareness initiative designed to fundamentally shift how healthcare professionals understand and approach attention-deficit/hyperactivity disorder (ADHD). As reported by FiercePharma.com, the company's "All of ADHD" campaign…

Continue Reading Beyond the Diagnosis: Otsuka’s “All of ADHD” Campaign Reframes Healthcare Provider Perspectives on a Complex Condition

FDA Grants Priority Review to Takeda’s Oveporexton: A Potential Game-Changer for Narcolepsy Type 1 Treatment

Takeda Pharmaceutical has reached a significant milestone in the development of oveporexton (TAK-861), with the US Food and Drug Administration officially accepting and granting Priority Review status to the investigational…

Continue Reading FDA Grants Priority Review to Takeda’s Oveporexton: A Potential Game-Changer for Narcolepsy Type 1 Treatment

CHMP Backs Novo Nordisk’s Semaglutide for MASH, Opening Door to EU Approval

As reported on MedicalXpress, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for several therapies this cycle, including a conditional endorsement…

Continue Reading CHMP Backs Novo Nordisk’s Semaglutide for MASH, Opening Door to EU Approval